Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights ...

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), making it the ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...